{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:15:46Z","timestamp":1788034546693,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jpet.2026.104976","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:25:44Z","timestamp":1782491144000},"page":"104976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bronchorelaxant and anti-inflammatory profile of ensifentrine alone and combined with inhaled medications in lipopolysaccharide-challenged human airways from chronic obstructive pulmonary disease donors"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-069X","authenticated-orcid":false,"given":"Luigino","family":"Calzetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Gholamalishahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jpet.2026.104976_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"9485","key":"10.1016\/j.jpet.2026.104976_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast\u2013an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"366","author":"Rabe","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2026.104976_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2024.102318","article-title":"Ensifentrine approval: a milestone in the treatment of COPD","volume":"87","author":"Calzetta","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.104976_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.jpet.2026.104976_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2023.2230138","article-title":"Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval","volume":"32","author":"Calzetta","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.jpet.2026.104976_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bph.16272","article-title":"Use of human airway smooth muscle in vitro and ex vivo to investigate drugs for the treatment of chronic obstructive respiratory disorders","volume":"181","author":"Calzetta","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104976_bib7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1124\/pharmrev.124.000951","article-title":"Drug-drug interactions and synergy: from pharmacological models to clinical application","volume":"76","author":"Calzetta","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.jpet.2026.104976_bib8","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/jpet.105.099192","volume":"318","author":"Boswell-Smith","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.jpet.2026.104976_bib9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1159\/000545645","article-title":"Anti-inflammatory activity of ensifentrine: a novel, selective dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4","volume":"104","author":"Rheault","year":"2025","journal-title":"Respiration"},{"issue":"11","key":"10.1016\/j.jpet.2026.104976_bib10","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1172\/JCI36130","article-title":"The cytokine network in asthma and chronic obstructive pulmonary disease","volume":"118","author":"Barnes","year":"2008","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jpet.2026.104976_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2174\/156801005774912806","article-title":"Inflammatory mediators in chronic obstructive pulmonary disease","volume":"4","author":"Chung","year":"2005","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"9","key":"10.1016\/j.jpet.2026.104976_bib12","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.mayocp.2021.03.016","article-title":"Why we should target small airways disease in our management of chronic obstructive pulmonary disease","volume":"96","author":"Usmani","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.jpet.2026.104976_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/07853890.2020.1831050","article-title":"Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease","volume":"53","author":"D\u2019Anna","year":"2021","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.jpet.2026.104976_bib14","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.chest.2020.11.018","article-title":"Interrelationships among small airways dysfunction, neutrophilic inflammation, and exacerbation frequency in COPD","volume":"159","author":"Day","year":"2021","journal-title":"Chest"},{"issue":"23","key":"10.1016\/j.jpet.2026.104976_bib15","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol\u2013glycopyrronium versus salmeterol\u2013fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.104976_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pupt.2014.02.001","article-title":"Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD","volume":"28","author":"Milara","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.104976_bib17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1124\/mol.112.083493","volume":"83","author":"Moodley","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104976_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2004.025692","article-title":"Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells","volume":"60","author":"Mata","year":"2005","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.jpet.2026.104976_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1183\/09031936.00135814","article-title":"Imprinting of the COPD airway epithelium for dedifferentiation and mesenchymal transition","volume":"45","author":"Gohy","year":"2015","journal-title":"Eur Respir J"},{"issue":"167","key":"10.1016\/j.jpet.2026.104976_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","volume":"32","author":"Calderon","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.jpet.2026.104976_bib21","doi-asserted-by":"crossref","first-page":"A5003","DOI":"10.1016\/j.chest.2023.07.3238","article-title":"Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, reduces exacerbation rate and risk regardless of exacerbation history in pooled enhance trial analyses","volume":"164","author":"Sciurba","year":"2023","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jpet.2026.104976_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s41030-021-00179-0","article-title":"First maintenance therapy for chronic obstructive pulmonary disease: retrospective analyses of US and UK healthcare databases","volume":"8","author":"Bloom","year":"2022","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jpet.2026.104976_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/14799731251314874","article-title":"Ensifentrine in COPD patients taking long-acting bronchodilators: a pooled post-hoc analysis of the ENHANCE-1\/2 studies","volume":"22","author":"Dransfield","year":"2025","journal-title":"Chron Respir Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104976_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpet.2026.104976_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2017.07.026","article-title":"Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi","volume":"812","author":"Calzetta","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104976_bib27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.113.204644","article-title":"Effect of the mixed phosphodiesterase 3\/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone","volume":"346","author":"Calzetta","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104976_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102050","article-title":"Ceiling effect of beclomethasone\/formoterol\/glycopyrronium triple fixed-dose combination in COPD: a translational bench-to-bedside study","volume":"69","author":"Rogliani","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jpet.2026.104976_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2015.03.007","article-title":"Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3\/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways","volume":"32","author":"Calzetta","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jpet.2026.104976_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105801","article-title":"Indacaterol, glycopyrronium, and mometasone: pharmacological interaction and anti-inflammatory profile in hyperresponsive airways","volume":"172","author":"Rogliani","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jpet.2026.104976_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2020.100010","article-title":"Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow\u2019s milk aspiration","volume":"2","author":"Ritondo","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"1","key":"10.1016\/j.jpet.2026.104976_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12931-016-0386-8","article-title":"Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells","volume":"17","author":"Cazzola","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.jpet.2026.104976_bib33","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/bph.15868","article-title":"Planning experiments: updated guidance on experimental design and analysis and their reporting III","volume":"179","author":"Curtis","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpet.2026.104976_bib34","series-title":"Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide To Curve Fitting","author":"Motulsky","year":"2004"},{"issue":"7","key":"10.1016\/j.jpet.2026.104976_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/13543784.2020.1769064","article-title":"Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD)","volume":"29","author":"Calzetta","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.jpet.2026.104976_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1164\/rccm.202308-1355LE","article-title":"Pharmacological interpretation of the efficacy of ensifentrine in chronic obstructive pulmonary disease: insights from ENHANCE trials","volume":"209","author":"Calzetta","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpet.2026.104976_bib37","article-title":"Drug interaction and chronic obstructive respiratory disorders","volume":"2","author":"Rogliani","year":"2021","journal-title":"Curr Res Pharmacol Drug Disc"},{"issue":"25","key":"10.1016\/j.jpet.2026.104976_bib38","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2016-09-737676","article-title":"Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies","volume":"128","author":"Cooney","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jpet.2026.104976_bib39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bcp.2008.07.025","article-title":"Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832\/13) cells and rat islets","volume":"76","author":"Waddleton","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104976_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13075-015-0771-6","article-title":"Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors","volume":"17","author":"Perez-Aso","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.jpet.2026.104976_bib41","doi-asserted-by":"crossref","first-page":"L534","DOI":"10.1152\/ajplung.00326.2005","article-title":"Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages","volume":"290","author":"Erdely","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104976_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1164\/rccm.200708-1217PP","article-title":"Airway smooth muscle in bronchial tone, inflammation, and remodeling: basic knowledge to clinical relevance","volume":"177","author":"Panettieri","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.104976_bib43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.chest.2024.07.168","article-title":"Effect of dual phosphodiesterase 3 and 4 inhibitor ensifentrine on exacerbation rate and risk in patients with moderate to severe COPD","volume":"167","author":"Sciurba","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.jpet.2026.104976_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1201658","article-title":"Mechanisms of airway epithelial injury and abnormal repair in asthma and COPD","volume":"14","author":"Raby","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2026.104976_bib45","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00589-2023","article-title":"The impact of the immune system on lung injury and regeneration in COPD","volume":"62","author":"Kapellos","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpet.2026.104976_bib46","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/1744666X.2025.2514604","article-title":"Mechanisms and therapeutic potential of epithelial-immune crosstalk in airway inflammation","volume":"21","author":"Chen","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104976_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12931-022-02208-1","article-title":"IL-10 producing regulatory B cells are decreased in blood from smokers and COPD patients","volume":"23","author":"Jacobs","year":"2022","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.jpet.2026.104976_bib48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/156652408785160907","article-title":"Role of IL-10 in the resolution of airway inflammation","volume":"8","author":"Ogawa","year":"2008","journal-title":"Curr Mol Med"},{"issue":"168","key":"10.1016\/j.jpet.2026.104976_bib49","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0193-2022","article-title":"Cytokine-targeted therapies for asthma and COPD","volume":"32","author":"Schleich","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.jpet.2026.104976_bib50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.chest.2017.04.174","article-title":"Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis","volume":"152","author":"Zider","year":"2017","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jpet.2026.104976_bib51","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.chest.2024.09.049","article-title":"The emerging role of alarmin-targeting biologics in the treatment of patients with COPD","volume":"167","author":"Celli","year":"2025","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jpet.2026.104976_bib52","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40265-017-0713-5","article-title":"Bringing stability to the chronic obstructive pulmonary disease patient: clinical and pharmacological considerations for frequent exacerbators","volume":"77","author":"Gulati","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jpet.2026.104976_bib53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2018.05.023","article-title":"Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells","volume":"832","author":"Matera","year":"2018","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2026.104976_bib54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1164\/rccm.202307-1164ED","article-title":"A new treatment for chronic obstructive pulmonary disease: ensifentrine moves closer","volume":"208","author":"Singh","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:23:23Z","timestamp":1788031403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022356526011766"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104976","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bronchorelaxant and anti-inflammatory profile of ensifentrine alone and combined with inhaled medications in lipopolysaccharide-challenged human airways from chronic obstructive pulmonary disease donors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104976"}}